SpaceX vs. Rocket Lab: Which Space Stock Has More Room to Run?

SpaceX could pursue a $1.75 trillion IPO, which would value the company at about 95 times 2025 sales and highlight its $18.5 billion revenue base, 68% four-year CAGR, and $8 billion 2025 net profit. Rocket Lab remains a much smaller but fast-growing competitor, with revenue rising from $62 million in 2021 to $602 million in 2025 and analysts projecting $1.6 billion by 2028 and profitability in 2027. The article is mainly comparative commentary on valuation and growth prospects rather than a new fundamental catalyst.

Analysis

The market is likely overusing SpaceX as a read-through for the whole space complex. If the IPO clears at a premium multiple, the immediate beneficiaries are not the launch names but the suppliers and systems integrators with cleaner revenue visibility, because public-market comparables tend to pull capital into adjacent picks-and-shovels before they rotate into the high-duration platform story. That makes the most interesting second-order trade less about whether Rocket Lab can ‘compete’ and more about whether its space-systems mix can re-rate toward defense-like software/mission-critical multiples if investors decide launch is a low-margin feature rather than the core product.

Rocket Lab’s real catalyst path is not Neutron alone; it is the combination of a credible heavy-lift roadmap plus a larger installed base of recurring spacecraft, components, and mission services. If execution stays on schedule, the market can begin discounting a broader operating leverage inflection 6-12 months ahead of profitability, which is often when the biggest multiple expansion occurs in infrastructure-tech hybrids. The risk is that any launch slip or test failure will matter disproportionately because the stock is priced for narrative continuity, not just execution.

The contrarian point is that a blockbuster SpaceX IPO may actually cap upside in the near term for Rocket Lab by increasing the intensity of ‘best-in-class’ comparisons. But over a 12-24 month horizon, a public SpaceX could also validate the category, expand the investor base, and force revaluation of every non-SpaceX space asset with defense exposure and recurring revenue. The key variable is whether investors treat SpaceX as a moonshot growth asset or as a margin benchmark that exposes the smaller player’s weaker economics; that distinction will drive whether the trade is momentum-positive or multiples-compressive.

Key Decisions for Investors

• Maintain a tactical long RKLB bias into major SpaceX IPO headlines, but size modestly and use a 6-9 month horizon; upside comes from category validation and multiple expansion, while downside is execution slippage and direct-comparison compression.
• Buy RKLB on post-rally pullbacks rather than pre-IPO hype; target entries after 8-12% drawdowns to improve asymmetry, since the stock is likely to be headline-sensitive and prone to sharp air pockets.
• Pair trade: long RKLB / short a space-adjacent basket with weaker recurring revenue and less defense exposure; the thesis is that capital will favor mission-critical systems over pure-launch beta if the IPO broadens the sector.
• Avoid chasing the SpaceX valuation story unless there is a clear path to public-market liquidity and profitability normalization; if the IPO prices above the implied sales multiple band, the risk/reward shifts from asymmetric to purely narrative-driven.
• For event-driven accounts, buy short-dated RKLB call spreads only after a confirmed Neutron milestone or SpaceX filing update; use defined risk because implied volatility should stay elevated and failures will be punished quickly.